The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer - Report from ESMO BC 2026 episode artwork

EPISODE · Jun 2, 2026 · 25 MIN

The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer - Report from ESMO BC 2026

from Medical Digest & Congress Report · host Medical Congress News

Professor Hope S. Rugo discusses the final overall survival results from the Phase 3 CAPItello-291 trial, evaluating the efficacy, long-term disease control, and safety of combining the AKT inhibitor capivasertib with fulvestrant for patients with AI-resistant, HR+/HER2− advanced breast cancer.Video: https://medicaldigest.org/scientific-contents/interview:capitello-291-trial-final-overall-survival-results-capivasertib-and-fulvestrant-hrher2-advanced-breast-cancer

Episode metadata supplied by the publisher feed · Published Jun 2, 2026

Embed this episode

Ready to play

The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer - Report from ESMO BC 2026

0:00 25:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 25 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on June 2, 2026.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!